A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology

Al-Batran, S.-E.; Mueller, D.W.; Rafiyan, M.-R.; Kiselicki, D.; Atmaca, A.; Habibzada, T.; Mueller, C.; Brignone, C.; Triebel, F.; Loose, M.; Schaaf, M.; Sookthai, D.; Eickhoff, R.; Jaeger, E.; Goetze, T.O.

doi:10.1016/j.esmoop.2023.101623

Cited by 3 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this trial showed promising therapeutic effects and good tolerability. Further investigation and validation of this combination will be conducted in future phase II studies ( 57 ). Following closely after is Vignali, Dario A.…”

Section: Descriptive Statisticsmentioning

confidence: 99%

Bibliometric analysis of evolutionary trajectory and prospective directions of LAG-3 in cancer

Wang,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

ObjectivesPerform a bibliometric analysis on the role of LAG-3 in the domain of cancer, elucidate the prevailing areas of research, and visually depict the evolutionary trajectory and prospective directions of LAG-3 research over the past twenty-three decades.Materials and methodsBetween 2000 and 2023, a comprehensive review of scholarly articles pertaining to LAG-3 research in the context of cancer was carried out using the Web of Science Core Collection (WoSCC) database. Bibliometric analysis can be conducted by taking advantage of VOSviewer (version 1.6.16) and CiteSpace (version 6.2.R4). Create a network diagram to visually represent various authors, countries, and organizations while assessing the publishing years, journals, references, and keywords.ResultsIn conclusion, 1841 records were identified and published in 587 publications. These records were authored by 12,849 individuals affiliated with 2491 institutes across 74 countries. There has been a substantial surge in publications subsequent to 2013. The USA, China, and Germany gave the majority of records, amounting to 69.69%. American institutions actively engage in collaboration with institutions located in other countries. Triebel, F., Vignali, Dario A. A., Workman, Creg J. Drake, Charles G., and Elkord, Eyad are highly regarded authors in their respective fields. However, it is worth noting that Triebel exhibits limited collaboration with other writers. The examination of the role of LAG-3 in cancer and its potential for use in clinical settings is a discernible trend, as seen by keyword analysis.ConclusionThe scientific interest in and attention towards LAG-3 has experienced a significant rise since 2013. The United States is leading the way, with China following closely behind. Promoting collaboration among writers, nations, and institutions with varied backgrounds is imperative. The discipline of immunotherapy is currently seeing ongoing progress. A thorough investigation of the distinctive cis ligand TCR-CD3 complex of LAG-3 and its signal transduction mechanism is necessary. Additionally, it is worthwhile to explore novel combinations of LAG-3 therapy.

show abstract

Section: Descriptive Statisticsmentioning

confidence: 99%

Bibliometric analysis of evolutionary trajectory and prospective directions of LAG-3 in cancer

Wang,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study

Krebs,

Forster,

Majem

et al. 2024

JTO Clinical and Research Reports

View full text Add to dashboard Cite

Advancements in the research of immune checkpoint inhibitors for the treatment of advanced esophageal squamous cell carcinoma

Sun

2024

Am J Cancer Res

View full text Add to dashboard Cite

Esophageal cancer (EC) has a high mortality rate and poor prognosis. Most patients are diagnosed at an advanced stage or with distant metastasis, making surgery impossible. Traditional curative radiotherapy and chemotherapy have limited efficacy. In recent years, with the development of clinical trials, immune checkpoint inhibitors (ICIs) have shown promising results in treating advanced and metastatic esophageal squamous cell carcinoma (ESCC) patients. ICIs have gradually become a primary therapeutic approach for EC. This review summarizes and provides an overview of the current research status and progress of ICIs in the treatment of advanced ESCC patients.

show abstract

A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology

Cited by 3 publications

References 48 publications

Bibliometric analysis of evolutionary trajectory and prospective directions of LAG-3 in cancer

Bibliometric analysis of evolutionary trajectory and prospective directions of LAG-3 in cancer

Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study

Advancements in the research of immune checkpoint inhibitors for the treatment of advanced esophageal squamous cell carcinoma

Contact Info

Product

Resources

About